As follow up, SFH convened a stakeholders meeting on Pre-exposure prophylaxis (PrEP) for HIV to share recent developments and evidence around PrEP as part of combination prevention package for HIV prevention on 15 June 2016 in Windhoek. Meeting was attended by over 50 participants representing CSOs, including KP-led organisations, Medical school – UNAM, Nambia HIV Clinician Society, MoHSS and UNAIDS and USAID.
Guest Speakers included: The World Health Organization, Ministry of Health and Social Services and Anova Health institute/EQUIP innovation for Health.
Outcome of the meeting: with ample evidence demonstrating that PrEP is highly effective for HIV prevention and the meeting recommended further dialogues with the Ministry of Health and Social Services to explore the possibility of expanding PrEP provision to people who are at substantial risk of HIV acquisition.
• Pre-Exporsure Prohylaxis (PrEP) refers to the use of TDF/FTC once daily in HIV negative people in order to reduce their risk of HIV infection
• PrEP is 92-100% effective and delivered in combination with other prevention services
• Requires daily adherence
• Approved by international and local guidelines
• PrEP is safe
• PrEP is not a lifelong medication
• PrEP is not HIV treatment
• PrEP does not lead to HIV drug resistance
• PrEP does not lead to increased risk behaviors
• PrEP is provided as part of a combination of HIV prevention tools
wordpress theme by initheme.com